A 58-year-old female is diagnosed with stage III, recurrent high-grade endometrioid ovarian cancer. She proceeds to treatment of her relapse with carboplatin and paclitaxel and achieves a partial response. Based on the results of the ARIEL3 trial, which of the following is true regarding the use of rucaparib in this setting?

A. Rucaparib is approved for use as maintenance for recurrent ovarian cancer only in the presence of a germline and/or somatic (BRCA) mutation

B. The use of rucaparib in patients with a response to platinum-based chemotherapy can result in improved progression-free survival

C. Patients with bulky disease or partial responses to treatment are less likely to respond to rucaparib

D. Rucaparib improved responses in patients with homologous recombination deficiency but not those who were homologous recombination–proficient